122 related articles for article (PubMed ID: 38905817)
21. Cost-effectiveness of efavirenz vs rilpivirine in HIV patients initiating first-line combination antiretroviral therapy.
Bonafede M; Juday T; Lenhart G; Pan K; Hebden T; Correll T
J Med Econ; 2013; 16(4):552-9. PubMed ID: 23391157
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Experienced (TE) Patients in France.
Pialoux G; Marcelin AG; Despiégel N; Espinas C; Cawston H; Finkielsztejn L; Laurisse A; Aubin C
PLoS One; 2015; 10(12):e0145885. PubMed ID: 26714188
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness of Dolutegravir in HIV-1 Treatment-Naive and Treatment-Experienced Patients in Canada.
Despiégel N; Anger D; Martin M; Monga N; Cui Q; Rocchi A; Pulgar S; Gilchrist K; Refoios Camejo R
Infect Dis Ther; 2015 Sep; 4(3):337-53. PubMed ID: 26099626
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lockman S; Brummel SS; Ziemba L; Stranix-Chibanda L; McCarthy K; Coletti A; Jean-Philippe P; Johnston B; Krotje C; Fairlie L; Hoffman RM; Sax PE; Moyo S; Chakhtoura N; Stringer JS; Masheto G; Korutaro V; Cassim H; Mmbaga BT; João E; Hanley S; Purdue L; Holmes LB; Momper JD; Shapiro RL; Thoofer NK; Rooney JF; Frenkel LM; Amico KR; Chinula L; Currier J;
Lancet; 2021 Apr; 397(10281):1276-1292. PubMed ID: 33812487
[TBL] [Abstract][Full Text] [Related]
25. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda.
Twimukye A; Laker M; Odongpiny EAL; Ajok F; Onen H; Kalule I; Kajubi P; Seden K; Owarwo N; Kiragga A; Armstrong-Hough M; Katahoire A; Mujugira A; Lamorde M; Castelnuovo B
BMC Infect Dis; 2021 Nov; 21(1):1154. PubMed ID: 34774018
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of antiretroviral drugs for treatment-naive HIV infection in China.
Li M; Cao Y; Huang H; Qin G; Chu M; Zou M; Zhuang X
BMC Public Health; 2023 Nov; 23(1):2228. PubMed ID: 37953277
[TBL] [Abstract][Full Text] [Related]
27. The Cost-Effectiveness of Dolutegravir in Combination with Tenofovir and Lamivudine for HIV Therapy: A Systematic Review.
Aprilianti S; Utami AM; Suwantika AA; Zakiyah N; Azis VI
Clinicoecon Outcomes Res; 2024; 16():25-34. PubMed ID: 38293254
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.
Pialoux G; Marcelin AG; Cawston H; Guilmet C; Finkielsztejn L; Laurisse A; Aubin C
Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):83-91. PubMed ID: 28741965
[TBL] [Abstract][Full Text] [Related]
29. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda.
Marseille E; Kahn JG; Pitter C; Bunnell R; Epalatai W; Jawe E; Were W; Mermin J
Appl Health Econ Health Policy; 2009; 7(4):229-43. PubMed ID: 19905037
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data.
Fernandes S; Sicuri E; Kayentao K; van Eijk AM; Hill J; Webster J; Were V; Akazili J; Madanitsa M; ter Kuile FO; Hanson K
Lancet Glob Health; 2015 Mar; 3(3):e143-53. PubMed ID: 25701992
[TBL] [Abstract][Full Text] [Related]
32. Effect of Dolutegravir-Based First-Line Antiretroviral Therapy on Mother-to-Child Transmission of HIV Among HIV-Exposed Infants in Ethiopia: a Before-and-After Study.
Facha W; Tadesse T; Wolka E; Astatkie A
HIV AIDS (Auckl); 2024; 16():203-215. PubMed ID: 38765704
[TBL] [Abstract][Full Text] [Related]
33. The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Girouard MP; Sax PE; Parker RA; Taiwo B; Freedberg KA; Gulick RM; Weinstein MC; Paltiel AD; Walensky RP
Clin Infect Dis; 2016 Mar; 62(6):784-91. PubMed ID: 26658053
[TBL] [Abstract][Full Text] [Related]
34. Is contraceptive self-injection cost-effective compared to contraceptive injections from facility-based health workers? Evidence from Uganda.
Di Giorgio L; Mvundura M; Tumusiime J; Morozoff C; Cover J; Drake JK
Contraception; 2018 Nov; 98(5):396-404. PubMed ID: 30098940
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study.
Tongtong Y; Shenghua H; Yin W; Lin C; Huanxia L; Chunrong L; Ruifeng Z; Xiaojing Y; Yuan Y; Yuanhong H; Ke Y
J Acquir Immune Defic Syndr; 2022 Oct; 91(S1):S1-S7. PubMed ID: 36094508
[TBL] [Abstract][Full Text] [Related]
36. Gestational diabetes in women living with HIV in Botswana: lower rates with dolutegravir- than with efavirenz-based antiretroviral therapy.
Mmasa KN; Powis K; Sun S; Makhema J; Mmalane M; Kgole S; Masasa G; Moyo S; Gerschenson M; Mohammed T; Legbedze J; Abrams EJ; Kurland IJ; Geffner ME; Jao J
HIV Med; 2021 Sep; 22(8):715-722. PubMed ID: 34003565
[TBL] [Abstract][Full Text] [Related]
37. Is pricing of dolutegravir equitable? A comparative analysis of price and country income level in 52 countries.
Sim J; Hill A
J Virus Erad; 2018 Oct; 4(4):230-237. PubMed ID: 30515303
[TBL] [Abstract][Full Text] [Related]
38. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
39. Population health impact, cost-effectiveness, and affordability of community-based HIV treatment and monitoring in South Africa: A health economics modelling study.
Sahu M; Bayer CJ; Roberts DA; van Rooyen H; van Heerden A; Shahmanesh M; Asiimwe S; Sausi K; Sithole N; Ying R; Rao DW; Krows ML; Shapiro AE; Baeten JM; Celum C; Revill P; Barnabas RV
PLOS Glob Public Health; 2023; 3(9):e0000610. PubMed ID: 37669249
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
Tremblay G; Chounta V; Piercy J; Holbrook T; Garib SA; Bukin EK; Punekar YS
Value Health Reg Issues; 2018 Sep; 16():74-80. PubMed ID: 30296624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
